Fig. 1: Survival outcomes by TKI use. | Blood Cancer Journal

Fig. 1: Survival outcomes by TKI use.

From: Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

Fig. 1

a, b Overall survival and relapse free survival for all patients treated with high intensity chemotherapy by TKI use, without censoring to allogeneic hematopoietic stem cell transplantation. c, d Overall survival and relapse free survival for all patients treated with low intensity chemotherapy by TKI usage, without censoring to allogeneic hematopoietic stem cell transplantation.

Back to article page